Olaparib, PARP1 inhibitor in ovarian cancer

Claudia Marchetti, Ludovica Imperiale, Maria Luisa Gasparri, Innocenza Palaia, Sandro Pignata, Terenzio Boni, Filippo Bellati, Pierluigi Benedetti Panici

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Introduction: Ovarian cancer is the most important cause of gynecological cancer-related mortality. Conventional treatments for advanced or recurrent disease offer limited results in terms of long-term responses and survival. Researches have recently focused on target therapies, which represent a new, promising, therapeutic approach, able to maximizing tumor kill and minimizing toxicity. The family of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors is currently one of the most hopeful and investigated alternatives. Areas covered: Preclinical and clinical studies of Olaparib, the most investigated PARP inhibitor in ovarian cancer, are analyzed and discussed. Data were obtained by searching for all English peer-reviewed articles on Medline, on Cochrane Database and all on-going Phase I and II studies registered on National Cancer Institute Clinical Trials; also any related abstracts recently presented on Olaparib at major international congresses will be included. Expert opinion: Bad prognosis and drug resistance usually affect ovarian cancer. Recent trends toward the knowledge of molecular-specific pathways have produced new target drugs. PARP inhibition mediated by Olaparib in BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2)-mutated and in sporadic ovarian cancer represents a promising field of investigation. Further studies are needed to confirm initial exciting results.

Original languageEnglish
Pages (from-to)1575-1584
Number of pages10
JournalExpert Opinion on Investigational Drugs
Volume21
Issue number10
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Ovarian Neoplasms
Ribose
Diphosphates
National Cancer Institute (U.S.)
Expert Testimony
Drug Resistance
Neoplasms
Clinical Trials
Databases
Breast Neoplasms
Mortality
olaparib
Therapeutics
Research
Pharmaceutical Preparations
polyadenosine

Keywords

  • BRCA1/2
  • Ovarian cancer
  • Polyadenosine diphosphate-ribose polymerase inhibitors
  • Target therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Marchetti, C., Imperiale, L., Gasparri, M. L., Palaia, I., Pignata, S., Boni, T., ... Benedetti Panici, P. (2012). Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opinion on Investigational Drugs, 21(10), 1575-1584. https://doi.org/10.1517/13543784.2012.707189

Olaparib, PARP1 inhibitor in ovarian cancer. / Marchetti, Claudia; Imperiale, Ludovica; Gasparri, Maria Luisa; Palaia, Innocenza; Pignata, Sandro; Boni, Terenzio; Bellati, Filippo; Benedetti Panici, Pierluigi.

In: Expert Opinion on Investigational Drugs, Vol. 21, No. 10, 10.2012, p. 1575-1584.

Research output: Contribution to journalArticle

Marchetti, C, Imperiale, L, Gasparri, ML, Palaia, I, Pignata, S, Boni, T, Bellati, F & Benedetti Panici, P 2012, 'Olaparib, PARP1 inhibitor in ovarian cancer', Expert Opinion on Investigational Drugs, vol. 21, no. 10, pp. 1575-1584. https://doi.org/10.1517/13543784.2012.707189
Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T et al. Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opinion on Investigational Drugs. 2012 Oct;21(10):1575-1584. https://doi.org/10.1517/13543784.2012.707189
Marchetti, Claudia ; Imperiale, Ludovica ; Gasparri, Maria Luisa ; Palaia, Innocenza ; Pignata, Sandro ; Boni, Terenzio ; Bellati, Filippo ; Benedetti Panici, Pierluigi. / Olaparib, PARP1 inhibitor in ovarian cancer. In: Expert Opinion on Investigational Drugs. 2012 ; Vol. 21, No. 10. pp. 1575-1584.
@article{20004ddb00f5404f8c4d240a95aa5fca,
title = "Olaparib, PARP1 inhibitor in ovarian cancer",
abstract = "Introduction: Ovarian cancer is the most important cause of gynecological cancer-related mortality. Conventional treatments for advanced or recurrent disease offer limited results in terms of long-term responses and survival. Researches have recently focused on target therapies, which represent a new, promising, therapeutic approach, able to maximizing tumor kill and minimizing toxicity. The family of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors is currently one of the most hopeful and investigated alternatives. Areas covered: Preclinical and clinical studies of Olaparib, the most investigated PARP inhibitor in ovarian cancer, are analyzed and discussed. Data were obtained by searching for all English peer-reviewed articles on Medline, on Cochrane Database and all on-going Phase I and II studies registered on National Cancer Institute Clinical Trials; also any related abstracts recently presented on Olaparib at major international congresses will be included. Expert opinion: Bad prognosis and drug resistance usually affect ovarian cancer. Recent trends toward the knowledge of molecular-specific pathways have produced new target drugs. PARP inhibition mediated by Olaparib in BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2)-mutated and in sporadic ovarian cancer represents a promising field of investigation. Further studies are needed to confirm initial exciting results.",
keywords = "BRCA1/2, Ovarian cancer, Polyadenosine diphosphate-ribose polymerase inhibitors, Target therapy",
author = "Claudia Marchetti and Ludovica Imperiale and Gasparri, {Maria Luisa} and Innocenza Palaia and Sandro Pignata and Terenzio Boni and Filippo Bellati and {Benedetti Panici}, Pierluigi",
year = "2012",
month = "10",
doi = "10.1517/13543784.2012.707189",
language = "English",
volume = "21",
pages = "1575--1584",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Olaparib, PARP1 inhibitor in ovarian cancer

AU - Marchetti, Claudia

AU - Imperiale, Ludovica

AU - Gasparri, Maria Luisa

AU - Palaia, Innocenza

AU - Pignata, Sandro

AU - Boni, Terenzio

AU - Bellati, Filippo

AU - Benedetti Panici, Pierluigi

PY - 2012/10

Y1 - 2012/10

N2 - Introduction: Ovarian cancer is the most important cause of gynecological cancer-related mortality. Conventional treatments for advanced or recurrent disease offer limited results in terms of long-term responses and survival. Researches have recently focused on target therapies, which represent a new, promising, therapeutic approach, able to maximizing tumor kill and minimizing toxicity. The family of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors is currently one of the most hopeful and investigated alternatives. Areas covered: Preclinical and clinical studies of Olaparib, the most investigated PARP inhibitor in ovarian cancer, are analyzed and discussed. Data were obtained by searching for all English peer-reviewed articles on Medline, on Cochrane Database and all on-going Phase I and II studies registered on National Cancer Institute Clinical Trials; also any related abstracts recently presented on Olaparib at major international congresses will be included. Expert opinion: Bad prognosis and drug resistance usually affect ovarian cancer. Recent trends toward the knowledge of molecular-specific pathways have produced new target drugs. PARP inhibition mediated by Olaparib in BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2)-mutated and in sporadic ovarian cancer represents a promising field of investigation. Further studies are needed to confirm initial exciting results.

AB - Introduction: Ovarian cancer is the most important cause of gynecological cancer-related mortality. Conventional treatments for advanced or recurrent disease offer limited results in terms of long-term responses and survival. Researches have recently focused on target therapies, which represent a new, promising, therapeutic approach, able to maximizing tumor kill and minimizing toxicity. The family of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors is currently one of the most hopeful and investigated alternatives. Areas covered: Preclinical and clinical studies of Olaparib, the most investigated PARP inhibitor in ovarian cancer, are analyzed and discussed. Data were obtained by searching for all English peer-reviewed articles on Medline, on Cochrane Database and all on-going Phase I and II studies registered on National Cancer Institute Clinical Trials; also any related abstracts recently presented on Olaparib at major international congresses will be included. Expert opinion: Bad prognosis and drug resistance usually affect ovarian cancer. Recent trends toward the knowledge of molecular-specific pathways have produced new target drugs. PARP inhibition mediated by Olaparib in BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2)-mutated and in sporadic ovarian cancer represents a promising field of investigation. Further studies are needed to confirm initial exciting results.

KW - BRCA1/2

KW - Ovarian cancer

KW - Polyadenosine diphosphate-ribose polymerase inhibitors

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=84866531335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866531335&partnerID=8YFLogxK

U2 - 10.1517/13543784.2012.707189

DO - 10.1517/13543784.2012.707189

M3 - Article

VL - 21

SP - 1575

EP - 1584

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 10

ER -